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Background: In the past, ABO incompatibility was an absolute contraindication for solid 
organ transplantation. However, multiple recent trials have suggested strategies for over-
coming the reactions between graft antigens and recipient antibodies that cause graft re-
jection. In this study, we determined the usefulness of plasma exchange (PE) for removing 
anti-A/B antibodies that cause hyperacute/acute humoral graft rejection in patients under-
going ABO-incompatible kidney transplantation.
Methods: In our study, 12 patients underwent ABO-incompatible kidney transplantation. 
All recipients received pre-transplantation conditioning by PE or intravenous immunoglob-
ulin (IVIG) administration. After pre-transplantation conditioning, anti-A/B antibody titers 
were evaluated, and transplantation was performed when the titer was below 1:8. To as-
sess the transplantation outcome, anti-A/B antibody titers, creatinine level, estimated glo-
merular filtration rate (eGFR), and proteinuria levels were measured.
Results: Anti-A/B antibody titers were below 1:8 in all patients at the time of transplanta-
tion. eGFR measured on post-transplant day 14 showed that 10 patients had immediate 
recovery of graft function, while 2 patients had slow recovery of graft function. Short-term 
outcomes of ABO-incompatible kidney transplantation (measured as creatinine levels) af-
ter reducing anti-A/B antibody titers were similar to those of ABO-compatible kidney trans-
plantation. After transplantation, the anti-A/B antibody titers were below 1:8 in 7 patients, 
but the remaining 5 patients required post-transplantation PE and IVIG treatment to pre-
vent antigen-antibody reactions.
Conclusions: With the increasing demand for kidney donations, interest in overcoming the 
ABO incompatibility barrier has increased. PE may be an important breakthrough in in-
creasing the availability of kidneys for transplantation.
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INTRODUCTION
For patients with chronic kidney disease, kidney transplantation 
is preferred over dialysis, because of the significantly superior 
survival rates of kidney transplantation. However, many patients 
are unable to receive transplants due to ABO mismatch. In Ko-
rea, patients awaiting kidney transplantation numbered 8,488 in 
2009, and only about 15% of these patients received kidney 
transplantation [1]. If ABO-incompatible kidney transplantations 
were possible, many more kidney transplantations could be per-
formed.
 To overcome the ABO incompatibility barrier, trials have at-
tempted to prevent the ABO antigen-antibody reactions to the 
graft. To prevent attack of anti-A/B antibodies on graft antigens, 
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anti-A/B antibody titers of the recipient must be reduced. Many 
reports on ABO-incompatible kidney transplantation have de-
scribed the removal of anti-A/B antibodies using therapeutic 
plasma exchanges (PEs). For removing anti-A/B antibodies, re-
moval of a recipient’s plasma through PE is reasonable. How-
ever, despite the historic and wide usage of therapeutic aphere-
sis, controlled clinical trials on PE for ABO-incompatible kidney 
transplantation have not been conducted [2]. In previous years, 
desensitization protocols involving splenectomy to induce a re-
duction in lymphoid mass and enhance efficacy of immunosup-
pressive medications were developed [3]. However, adverse ef-
fects and suboptimal efficacy were noted after splenectomy. 
Currently, studies are being conducted on the use of PE and in-
travenous immunoglobulin (IVIG), along with immunosuppres-
sants, but without splenectomy [4]. This study reports 12 cases 
of ABO-incompatible kidney transplantation that received PE 
followed by IVIG and immunosuppressant administration.
METHODS
1. Patients
Between June 2010 and May 2011, 12 patients received kidney 
transplantations from ABO-incompatible living donors at the 
Yonsei University Health System (YUHS), which is affiliated with 
Severance Hospital, Seoul, Korea. These patients had end stage 
renal disease and were unable to find ABO-compatible donors; 
however, each of them had a family member who intended to 
donate his or her kidney. All patients received pre-transplanta-
tion conditioning prior to the operation. Results of the HLA 
crossmatch test that included testing of the antihuman-globulin 
phase were negative for all patients.
2. Protocol for pre-transplantation conditioning
We used the conditioning protocol illustrated in Fig. 1, as previ-
ously reported [5]. The YUHS protocol consists of PE followed 
by IVIG (100 mg/kg) and immunosuppressants (tacrolimus 0.1 
mg/day, mycophenolate 1,500 mg/day, prednisone 20 mg/day, 
rituximab 375 mg/m2) administration. The medical staff ex-
plained the pre-transplantation conditioning protocol to all pa-
tients, and all patients provided informed consent for the proto-
col. PE was conducted using the COBE spectra system (Gam-
bro BCT, Lakewood, CO, USA) for the patients who had anti-A/B 
antibody titers greater than 1 :8. One plasma volume was re-
moved from each patient, and 100% replacement was provided 
using a 5% albumin solution and fresh frozen plasma (FFP) of 
AB blood group. PE and IVIG treatments were conducted every 
other day before transplantation until both IgM and IgG titers 
were under 1 :8. PE was performed with 5% normal serum al-
bumin for the initial sessions, and the last 2 sessions of PE were 
carried out with AB blood group FFP. Immunosuppressive drugs 
were used before transplantation to prevent graft rejection. Ad-
ministration of tacrolimus, mycophenolate, and prednisone was 
initiated 7 days prior to transplantation, and administration of 
rituximab was performed 2 days before transplantation. Sple-
nectomy was not included in the conditioning protocol.
3. Measurement of anti-A/B antibody titers
Anti-A/B antibody titers were determined by testing two-fold se-
rial dilutions of the patients’ serum with commercially available 
A/B indicator red cells [6]. The highest serum dilution ratio that 
showed 1+ reactivity indicated the anti-A/B antibody titers. IgG 
titers were measured using serum samples treated with dithio-
threitol, while IgM titers were determined from untreated sam-
ples. Antibody titers were evaluated every day after initiation of 
the conditioning protocol.
4. Estimated glomerular filtration rate and proteinuria
Graft function was evaluated by considering the estimated glo-
merular filtration rate (eGFR) and level of proteinuria. Serum cre-
atinine levels were measured by the Jaffe method on a Hitachi 
7600-210 autoanalyzer (Hitachi Co. Ltd., Tokyo, Japan) using 
Daiichi creatinine (Daiichi Pure Chemicals Co. Ltd., Tokyo, Ja-
pan). eGFR was estimated from the serum creatinine levels using 
Fig. 1. Desentization protocol for ABO-incompatible living donor kid-
ney transplantation at Yonsei University Health System.
Abbreviations: PE, plasma exchange; IVIG, intravenous immunoglobulin; KT, 
kidney transplantation.
Tacrolimus 0.1 mg/day
Mycophenolate 1,500 mg/day
Troughlevel : 5-8 ng/mL
Methylprednisolone
Basiliximab IVRituximab IV
PE/IVIG (100 mg/kg)
Prednisone 20 mg/day
-7 -2 (day)7KT
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the abbreviated Modification of Diet in Renal Disease formula [7]. 
Renal function after the operation was categorized into the im-
mediate recovery of graft function (IGF) or slow recovery of graft 
function (SGF) group on the basis of the eGFR on post-transplant 
day (POD) 14. Delayed recovery of graft function (DGF) was de-
fined as the need for dialysis within 7 days after transplantation. 
The level of proteinuria was measured by the semiquantitative 
method using an automated urine analyzer. The reflectance of 
the surface of URiSCAN Super test strips (YD Diagnostics, Yon-
gin, Korea) was evaluated using a reflectance photometer after 
the strip was reacted with the patients’ urine samples.
RESULTS
1. Characteristics of recipients and donors 
Information on the recipients is provided in Table 1. Of the 12 
recipients, 7 were women and 5 were men. The median age of 
the recipients was 51 yr (average age, 48.75 yr; range, 23-60 yr). 
All patients received major ABO-mismatched grafts, with no 
weak ABO subgroups among the donors. No patient showed 
hyperacute rejection after transplantation, and loss of grafts did 
not occur during the hospitalization period.
2. Anti-A/B antibody titers
Anti-A/B antibody titers were recorded on the day before initia-
tion of PE and IVIG administration, the day of transplantation, 
the time of discharge from hospital, and at 1 month after trans-
plantation (Table 1). The initial anti-A/B antibody titers of the pa-
tients were 1 :8-1 :128, and the titers decreased in response to 
PE and IVIG administration to 1 :8 in all patients. The average 
number of pre-transplantation PE and IVIG treatments was 4.0
±0.89 (range 3-5). In general, the higher the initial antibody ti-
ter, the greater the number of pre-transplantation treatments re-
quired. However, patient 2 needed 5 treatments of PE and IVIG 
before transplantation due to a low response to treatment. 
 Most of the patients’ antibody titers at the time of discharge 
Table 1. Patient characteristics and anti-A/B antibody titers
Patient 
number
Donor 
ABO
Recipient 
ABO
Recipients Initial titers* Number of 
pre-op PE and 
IVIG†
Titer at 
transplantation*
Number of 
post-op PE and 
IVIG‡
Titers at discharge 
from hospital*
Titers at 1 month 
after 
transplantation*
Age Gender IgM IgG IgM IgG IgM IgG IgM IgG
 1 B+ A+ 58 F 1:64 1:64 5 1:2 1:2 0 1:2 1:2 1:2 1:2
 2 AB+ A+ 60 M 1:8 1:16 5 1:2 1:2 1 (POD#9) 1:2 1:8 1:2 8
 3 A+ B+ 47 F 1:32 1:16 4 1:2 1:4 0 1:2 1:8 1:2 1:4
 4 AB+ B+ 51 M 1:128 1:64 4 1:2 1:4 2 (POD#5, 8) 1:4 1:16 1:4 1:16
 5 A+ B+ 47 M 1:16 1:4 3 1:2 1:2 2 (POD#5, 15) 1:8 1:4 1:16 1:8
 6 A+ O+ 23 F 1:128§ 1:128§ 5 1:4§ 1:8§ 1 (POD#6) 1:16§ 1:16§ 1:16§ 1:16§
 7 A+ B+ 56 F 1:16 1:4 4 1:4 1:4 0 1:2 1:2 1:4 1:2
 8 A+ O+ 46 F 1:64§ 1:64§ 5 1:2§ 1:4§ 1 (POD#6) 1:4§ 1:32§ 1:4§ 1:32§
 9 B+ A+ 51 M 1:32 1:2 3 1:2 1:2 0 1:1 1:2 1:1 1:2
10 B+ A+ 52 M 1:16 1:4 3 1:1 1:1 0 1:1 1:4 1:1 1:2
11 B+ O+ 54 F 1:32|| 1:128|| 5 1:1|| 1:2|| 0 1:2|| 1:8|| 1:2|| 1:8||
12 B+ A+ 40 F 1:8 1:2 3 1:1 1:4 0 1:1 1:4 1:1 1:2
*Antibody titers assessed using the tube method; †Number of pre-transplant PE and IVIG treatments; ‡Number of post-transplant PE and IVIG treatments; 
§The anti-A antibody titers; ||The anti-B antibody titers.
Abbreviations: pre-op, pre-operative; post-op, post-operative; PE, plasma exchange; IVIG, intravenous immunoglobulin; POD, post-transplant day.
Table 2. ABO-IgG antibody titers before and after post-transplanta-
tion PE and IVIG treatment in patients who had antibody titers of over 
1:16 after transplantation
Antibody IgG titer
Post-op PE and IVIG #1 Post-op PE and IVIG #2
Before PE 
and IVIG
After PE 
and IVIG
Before PE 
and IVIG
After PE 
and IVIG
IgG titer of patient 2 1:16 1:8
IgG titer of patient 4 1:16 1:16 1:16 1:16
IgG titer of patient 5 1:16 1:8 1:16 1:4
IgG titer of patient 6 1:16 1:8
IgG titer of patient 8 1:16 1:16
Abbreviations: post-op, post-operative; PE, plasma exchange; IVIG, intrave-
nous immunoglobulin.
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from hospital were higher than the titers at transplantation but 
lower than their initial titers. Post-transplantation PE and IVIG 
treatment was performed with 5% albumin solution in order to 
reduce anti-A/B antibody titers to below 1:16 to avoid rejection 
in 5 patients (patients 2, 4, 5, 6, and 8). In patients 2 and 5, 
post-transplantation PE and IVIG administration was effective at 
lowering antibody titers; however, in patients 4 and 8, anti-A/B 
antibody titers did not respond to PE and IVIG administration. In 
patient 6, ABO IgG antibody titers were 1 :8 after post-transplan-
tation PE and IVIG administration, but were 1 :16 at discharge 
(Table 2).
3. eGFR and proteinuria
After transplantation, serum creatinine levels, eGFR, and pro-
teinuria showed improvement in all patients. The average creati-
nine levels at 1 week, 2 weeks, and 1 month after transplanta-
tion were 1.30, 1.06, and 1.18 mg/dL, respectively. No patient 
underwent dialysis after transplantation i.e. no patient showed 
DGF. The eGFR at POD 14 was computed as over 60 in 10 of 
the 12 patients, suggesting IGF, while 2 patients (patients 6 and 
10) showed eGFR of less than 60, which indicated SGF. Protein-
uria due to glomerular damage was negligible in all recipients 
(Table 3).
DISCUSSION
All patients showed graft success and good decrease in serum 
creatinine level. The average creatinine level at discharge was 
1.13 mg/dL, and the average period from transplant to discharge 
was 18.25 days. The average creatinine level of patients who 
underwent ABO-compatible kidney transplantation at YUHS be-
tween 1997 and 2002 was 1.86 mg/dL and 1.58 mg/dL at 1 week 
and 1 month after transplant, respectively [8]. The short-term 
outcomes of ABO-incompatible kidney transplantation were 
similar to those of ABO-compatible kidney transplantation.
 Since the concept of depleting anti-A/B antibody using PE 
was introduced to overcome the donor-recipient ABO-incompat-
ibility in kidney transplantation, many trials were conducted for 
several decades. The outcome of ABO-incompatible kidney 
transplants has been improved and introduction of tacrolimus/
mycophenolate mofetil has been regarded as major factor that 
made a difference [9]. In Korea, successful outcomes without 
graft loss were reportd in ABO-incompatible kidney transplants 
pretreated with PE, tacrolimus, mycophenolate mofetil and 
rituximab [10, 11]. Compared to IGF, DGF and SGF i.e. poor 
early graft function is associated with higher rates of acute rejec-
tion and impaired renal allograft survival [12]. We predict good 
prognosis for patients who showed IGF in this study and poor 
prognosis for patients with SGF, who may require a renal biopsy 
for diagnosis of rejection. 
 Antibody-mediated rejection is a significant risk to the survival 
of patient and graft. Donor-specific anti-HLA antibodies are more 
closely associated with rejection than anti-A/B antibodies; never-
theless, prevention of immune reactions due to anti-A/B anti-
Table 3. Serum creatinine levels, eGFR, and urine protein levels of the patients at the time of transplant and at discharge from the hospital
Patient 
number
Creatinine (mg/dL) eGFR Urinary protein (semiquantitative)
At op* At discharge† At POD 14‡ At op* At discharge† At POD 14‡ At op* At discharge†
 1 3.26 0.81 0.72 15.50 77.31 88.57 +/- -
 2 6.49 1.35 1.19 9.37 57.39 66.38 2+ -
 3 7.41 1.10 1.02 6.27 56.68 61.84 3+ -
 4 6.45 1.32 1.23 9.92 60.87 66.04 1+ -
 5 1.41 1.30 1.34 57.36 62.99 60.83 - -
 6 10.43 1.38 1.54 4.89 50.44 44.44 +/- -
 7 4.96 0.76 0.64 9.62 83.81 102.19 2+ -
 8 4.26 1.01 1.02 11.93 59.00 62.11 - -
 9 5.13 1.05 0.93 12.71 74.00 86.00 2+ -
10 4.92 1.29 1.45 13.28 58.00 51.00 2+ -
11 5.53 1.27 0.73 8.00 44.00 83.00 - +/-
12 5.57 0.90 0.87 8.00 69.00 72.00 - -
*Measured value at operation; †Measured value at discharge from a hospital; ‡Measured value at POD 14.
Abbreviations: eGFR, estimated glomerular filtration rate; op, operation; POD, post-transplant day.
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bodies is crucial for transplant success. ABO antigens are ex-
pressed not only on red blood cells but also in various cells such 
as the endothelial cells of graft organs. ABO-incompatible graft 
implantation often results in immediate hyperacute rejection, in-
volving failure of graft reperfusion due to thrombosis of the mi-
crovasculature [13]. Titers of the anti-A/B IgG antibodies are 
considered to be more important than titers of IgM. Gloor et al. 
reported that initial anti-A/B IgG titer of more than 1:256 is sig-
nificantly associated with the incidence of antibody-mediated re-
jection [14]. Further, Toki et al. reported that an anti-A/B IgG titer 
above 1 :32 at the time of transplantation is an independent risk 
factor for antibody-mediated rejection [15]. In this study, patient 
6 and patient 11 had the highest initial anti-A/B IgG titers (1 :128) 
and had the lowest eGFR at 50.44 and 44.00, respectively. 
 PE is used to reduce titers of anti-A/B antibodies, but PE does 
not eliminate only the anti-A/B antibodies in the plasma. Along 
with antibodies, plasma constituents are also removed by PE. 
Theoretically, one-volume PE should lead to removal of 70% of 
the substances in plasma [16], but actually, efficiency of PE is 
lowered due to the movement of extravascular substances to the 
intravascular compartments and resynthesis of plasma sub-
stances [17]. 
 Accordingly, 5% albumin solution and AB blood group FFP 
were used as replacement fluids during PE. Use of albumin in-
volves a minimal risk of infectious disease and rarely causes any 
allergic reaction. For removing plasma substances without caus-
ing any deficits in the plasma, albumin is the most appropriate 
replacement fluid. Usually, albumin is preferred to FFP because 
compared to albumin, FFP is associated with higher risk of hy-
persensitivity reactions and transmission of viral infections [18]. 
However, in this study, the last 2 PEs immediately before the 
transplantation were performed with FFP to supply coagulation 
factors to the patients in order to assuage the worry of surgeons 
concerning bleeding during operation. Furthermore, soluble 
ABO antigens present in the FFP can neutralize recipients’ iso-
agglutinins. Therefore, FFP, as a replacement fluid, can possibly 
help to reduce the recipient’s anti-A/B antibody titers [17].
 IVIG administration can play a role in the reduction of antibody 
titers, but the exact mechanism is not well defined. It is thought 
that IVIG suppresses the rebound of antibody titers right after 
PE. In addition, IVIG is administered after PE to prevent exces-
sive hypogammaglobulinemia. 
 Post-transplantation PE and IVIG treatments were related to 
successful renal transplantation during the study period; this 
may be attributed to a decrease in anti-A/B antibody titers. Low-
ering the anti-A/B antibody titers by PE and IVIG administration 
prevented aggravation of antibody-mediated rejection, allowing 
for successful renal graft functioning. In this study, 5 out of the 
12 patients underwent post-transplantation PE and IVIG treat-
ment. Table 2 shows the changes in anti-A/B antibody titers be-
fore and after post-transplantation PE and IVIG treatments. 
Among these 5 patients, 3 patients (patients 2, 5, and 6) showed 
a decrease in antibody titers after post-transplantation PE and 
IVIG treatment, but the antibody titers of patient 6 increased 
right before discharge from hospital. As a result, only 2 patients 
showed IgG titers within the target range at the time of dis-
charge. Patients 4, 6, and 8 had high ABO IgG titers and re-
quired a more number of pre-transplantation PE and IVIG treat-
ments than the other 2 patients. The degree of response to pre-
transplantation PE and IVIG treatment appeared to be associ-
ated with the degree of response to post-transplantation PE and 
IVIG treatment. 
 PE is currently considered as a supportive therapy for ABO-
incompatible kidney transplantation. Procedures that remove a 
recipient’s anti-A/B antibodies are essential for ABO-incompati-
ble kidney transplantation. Protocols for pre-transplantation de-
sensitization should include antibody removal process. PE may 
help overcome the barrier of ABO incompatibility by removing 
the recipient’s natural antibodies against the donor’s A and/or 
B blood group antigens. We suggest that PE be considered as a 
primary therapy for ABO-incompatible kidney transplantation.
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